Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of a liver disease – primary biliary cholangitis (PBC).
Copyright © 2024 | WordPress Theme by MH Themes